Dashboard
Manage Tickers

NVCR NovoCure Ltd

Nasdaq novocure.com


$ 13.43 $ 0.03 (0.22 %)    

Wednesday, 29-Oct-2025 09:40:03 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 635.54 $ -0.01 (-0 %)
DIA $ 479.15 $ 0.49 (0.1 %)
SPY $ 688.74 $ 0.03 (0 %)
TLT $ 91.81 $ -0.07 (-0.08 %)
GLD $ 368.39 $ -1.31 (-0.36 %)
$ 13.37
$ 13.40
$ 13.40 x 1
$ 13.46 x 16
$ 13.40 - $ 13.43
$ 10.87 - $ 34.13
1,058,916
na
1.49B
$ 1.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-30-2025 10-Q
2 04-24-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 10-26-2023 09-30-2023 10-Q
9 07-27-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 10-27-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-25-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 10-25-2018 09-30-2018 10-Q
29 07-26-2018 06-30-2018 10-Q
30 04-26-2018 03-31-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-27-2017 06-30-2017 10-Q
34 04-27-2017 03-31-2017 10-Q
35 02-23-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-01-2016 12-31-2015 10-K
40 10-27-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-neutral-on-novocure-lowers-price-target-to-23
JP Morgan Maintains Neutral on NovoCure, L...
10/27/2025 14:36:30

JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $25 to $23.

novocure-to-present-ttfields-data-at-eano-prague-oct-1619-and-esmo-berlin-oct-1721-highlights-radiosensitization-in-glioblastoma-and-panova-3-post-hoc-in-pancreatic-cancer
Novocure To Present TTFields Data At EANO ...
10/15/2025 11:02:03

novocure-to-present-final-results-from-phase-3-metis-trial-of-tumor-treating-fields-therapy-for-brain-metastases-from-nsclc-at-2025-astro
Novocure To Present Final Results From Pha...
09/29/2025 20:32:06

METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in pat...

japans-ministry-of-health-labour-and-welfare-approves-novocures-optune-lua-for-concurrent-use-with-pd-1pd-l1-inhibitors-for-adult-patients-with-unresectable-advancedrecurrent-non-small-cell-lung-cancer-who-have-progressed-on-or-after-platinum-based-chemotherapy
Japan's Ministry Of Health, Labour And Wel...
09/15/2025 11:03:45

Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTF...

novocure-terminates-lunar-4-trial-decision-not-related-to-safety-concerns
NovoCure Terminates LUNAR-4 Trial, Decisio...
08/28/2025 11:13:16

novocure-expands-access-to-tumor-treating-fields-therapy-in-spain-for-adult-patients-with-newly-diagnosed-glioblastoma
Novocure Expands Access To Tumor Treating ...
08/25/2025 11:09:59

novocure-submits-premarket-approval-application-to-the-fda-for-tumor-treating-fields-therapy-for-locally-advanced-pancreatic-cancer
Novocure Submits Premarket Approval Applic...
08/20/2025 11:01:58

top-3-health-care-stocks-that-may-explode-in-july
Top 3 Health Care Stocks That May Explode ...
07/28/2025 10:52:30

wells-fargo-downgrades-novocure-to-equal-weight-lowers-price-target-to-145
Wells Fargo Downgrades NovoCure to Equal-W...
07/25/2025 13:22:13

Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price t...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/24/2025 17:06:06

novocure-q2-2025-eps-036-beats-039-estimate-sales-158805m-beat-153876m-estimate
NovoCure Q2 2025 EPS $(0.36) Beats $(0.39)...
07/24/2025 11:00:57

Core News & Articles
Earnings Scheduled For July 24, 2025
07/24/2025 08:32:31

novocure-earnings-preview
NovoCure Earnings Preview
07/23/2025 21:02:00

this-circle-internet-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-tuesday
This Circle Internet Analyst Begins Covera...
07/08/2025 12:53:27

ladenburg-thalmann-initiates-coverage-on-novocure-with-buy-rating-announces-price-target-of-30
Ladenburg Thalmann Initiates Coverage On N...
07/08/2025 12:17:18

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on NovoCure (NASDAQ:NVCR) with a Buy rating and announces Price...

novocure-to-present-final-panova-3-secondary-data-at-esmo-gi-2025-ttfields-shows-pain-relief-qol-gains-in-pancreatic-cancer
Novocure To Present Final PANOVA-3 Seconda...
07/01/2025 11:09:41

demystifying-novocure-insights-from-4-analyst-reviews
Demystifying NovoCure: Insights From 4 Ana...
06/27/2025 18:01:19

piper-sandler-reiterates-overweight-on-novocure-maintains-34-price-target
Piper Sandler Reiterates Overweight on Nov...
06/27/2025 16:35:13

Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and maintains $34 price target.

applied-digital-and-riot-platforms-are-among-top-10-mid-cap-gainers-last-week-jun-2-jun-6-are-the-others-in-your-portfolio
Applied Digital And Riot Platforms Are Amo...
06/08/2025 15:45:33

novocures-tumor-treating-fields-boost-one-year-and-pain-free-survival-in-pancreatic-cancer-trial
NovoCure's Tumor Treating Fields Boost One...
06/02/2025 18:05:17

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data fr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION